📄
Novel B-Cell targeting therapy with subcutaneous of atumumab in AQP4-IgG-seronegative Neuromyelitis Optica Spectrum Disorders: efficacy and personalized dosing.
active
paper
Created:
By: unknown
Quality:
50%
✓ SciDEX
ID: paper-41909718
📄 Paper Details
Novel B-Cell targeting therapy with subcutaneous of atumumab in AQP4-IgG-seronegative Neuromyelitis Optica Spectrum Disorders: efficacy and personalized dosing.
Cao X, Qin D, Wang B, Wang C, Guo S
Abstract
BACKGROUND AND OBJECTIVES: AQP4-IgG-seronegative Neuromyelitis Optica Spectrum Disorders (AQP4-IgG-seronegative NMOSD) represent a distinct and rare subtype of Neuromyelitis Optica Spectrum Disorders (NMOSD). Diagnosis and management of this condition pose significant challenges in clinical practice. Here, we present two cases of AQP4-IgG-seronegative NMOSD, which demonstrated a favorable response to personalized ofatumumab (OFA) therapy. METHODS: Two patients, confirmed negative for both AQP4-I...
▸Metadata
| _schema_version | 1 |
📊 Evidence Profile
Evidence Balance
+0%
Certainty
5%
Debates
0
Incoming
1
Outgoing
1
0 supporting
0 contradicting
0 neutral
Public annotations (0)Annotate on Hypothes.is →
No public annotations yet.